Physician profile
Hara Lam
NPI 1467805762
$2,096.57
in general payments reported to CMS, 2019-2025
13 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $289 · 2021: $321 · 2022: $388 · 2023: $398 · 2024: $197 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $617.28 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $365.68 | 2019-2025 | Precision 1, Dailies |
| Bausch & Lomb Americas INC. | $321.26 | 2022-2025 | Infuse, Xiidra, Miebo |
| Mallinckrodt Hospital Products INC. | $191.83 | 2022-2023 | Acthar |
| Ivantis, INC | $158.63 | 2021 | |
| Glaukos Corporation | $154.38 | 2020 | |
| Biotissue Holdings INC. | $118.06 | 2020-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.50 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $40.70 | 2022 | |
| Oyster Point Pharma, INC. | $26.06 | 2023 | Tyrvaya |
| Abbvie INC. | $18.29 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $17.73 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $14.17 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hara Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.